Medigene AG to be included in TecDAX
Medigene AG has been selected for inclusion on the TecDAX, an index of the Deutsche Börse (German Stock Exchange) that includes Germany's most important mid-cap technology companies.
The TecDAX follows the Blue Chip DAX index and comprises 30 companies admitted to the stock market "Prime Standard" segment. In addition to compliance with comprehensive international transparency requirements, the admission criteria include an above-average market capitalization (share price multiplied by the number of company shares), and a high trading volume (number of shares traded daily).
According to the decision made by Deutsche Börse on 5 December 2016, Medigene has fulfilled the admission criteria for the TecDAX and will be included there as of 19 December 2016.
Prof Dolores Schendel, CEO of Medigene AG, comments: "TecDAX membership signifies Medigene's position among the leading German technology securities. This admission reflects the dynamic development Medigene has made following its strategic refocussing on the development of highly innovative cancer immunotherapies. The TecDAX listing increases Medigene's visibility in the capital markets and facilitates our collaboration with domestic and international investors."
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.